149 related articles for article (PubMed ID: 24219003)
1. CD26: a multi-purpose pharmacological target.
Vincenzo F; Manfredi T; Carmine C; Mario R
Curr Clin Pharmacol; 2014 May; 9(2):157-64. PubMed ID: 24219003
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases.
Hu X; Wang X; Xue X
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889373
[TBL] [Abstract][Full Text] [Related]
3. Critical Role of Dipeptidyl Peptidase IV: A Therapeutic Target for Diabetes and Cancer.
De S; Banerjee S; Kumar SKA; Paira P
Mini Rev Med Chem; 2019; 19(2):88-97. PubMed ID: 29692250
[TBL] [Abstract][Full Text] [Related]
4. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
Klemann C; Wagner L; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jul; 185(1):1-21. PubMed ID: 26919392
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
6. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
Panchapakesan U; Mather A; Pollock C
Clin Sci (Lond); 2013 Jan; 124(1):17-26. PubMed ID: 22963445
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Fadini GP; Avogaro A
Vascul Pharmacol; 2011; 55(1-3):10-6. PubMed ID: 21664294
[TBL] [Abstract][Full Text] [Related]
8. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
Ohm B; Moneke I; Jungraithmayr W
Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
[TBL] [Abstract][Full Text] [Related]
9. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.
Anderluh M; Kocic G; Tomovic K; Kocic R; Deljanin-Ilic M; Smelcerovic A
Pharmacol Ther; 2016 Nov; 167():100-107. PubMed ID: 27484974
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018).
Hussain H; Abbas G; Green IR; Ali I
Expert Opin Ther Pat; 2019 Jul; 29(7):535-553. PubMed ID: 31203700
[TBL] [Abstract][Full Text] [Related]
11. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
Marguet D; Baggio L; Kobayashi T; Bernard AM; Pierres M; Nielsen PF; Ribel U; Watanabe T; Drucker DJ; Wagtmann N
Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6874-9. PubMed ID: 10823914
[TBL] [Abstract][Full Text] [Related]
12. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
Singh AK; Jatwa R; Purohit A; Ram H
J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
[TBL] [Abstract][Full Text] [Related]
13. Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.
Alonso N; Julián MT; Carrascal J; Colobran R; Pujol-Autonell I; Rodriguez-Fernández S; Teniente A; Fernández MA; Miñarro A; Ruiz de Villa MC; Vives-Pi M; Puig-Domingo M
PLoS One; 2015; 10(11):e0142186. PubMed ID: 26555789
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 based therapy for type 2 diabetes.
Arulmozhi DK; Portha B
Eur J Pharm Sci; 2006 May; 28(1-2):96-108. PubMed ID: 16488579
[TBL] [Abstract][Full Text] [Related]
15. A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice.
Li Z; Fang J; Jiao R; Wei X; Ma Y; Liu X; Cheng P; Li T
Biomed Pharmacother; 2017 May; 89():1467-1475. PubMed ID: 28376584
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
Yamagishi S; Matsui T
Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
[TBL] [Abstract][Full Text] [Related]
17. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS - a critical overview.
Bernstein HG; Keilhoff G; Dobrowolny H; Steiner J
Rev Neurosci; 2023 Jan; 34(1):1-24. PubMed ID: 35771831
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.
Yaribeygi H; Sathyapalan T; Sahebkar A
Life Sci; 2019 Oct; 234():116776. PubMed ID: 31425698
[TBL] [Abstract][Full Text] [Related]
19. CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders.
Thompson MA; Ohnuma K; Abe M; Morimoto C; Dang NH
Mini Rev Med Chem; 2007 Mar; 7(3):253-73. PubMed ID: 17346218
[TBL] [Abstract][Full Text] [Related]
20. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
Cariou B
Diabetes Metab; 2012 Oct; 38(4):298-308. PubMed ID: 22672960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
